Atossa Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology, has recently reported significant developments related to its lead candidate, (Z)-Endoxifen. Two key announcements highlight the progress of (Z)-Endoxifen in clinical trials for breast cancer treatment and prevention, indicating a robust pipeline aimed at addressing unmet medical needs in this area.
The company announced positive results from the KARISMA trial, which investigated the effects of (Z)-Endoxifen on mammographic breast density a notable factor in assessing breast cancer risk. The trial findings suggest that (Z)-Endoxifen significantly reduces mammographic breast density, paving the way for novel strategies in cancer prevention. Lower breast density is associated with a decreased risk of developing breast cancer, positioning (Z)-Endoxifen as a potentially valuable agent in prophylactic treatment approaches.
In addition to the KARISMA trial, Atossa has recently completed the enrollment of an 80 mg pharmacokinetic (PK) run-in cohort in its Phase 2 EVANGELINE clinical trial. This trial aims to evaluate (Z)-Endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / HER2 negative (HER2-) breast cancer. The randomized non-inferiority study compares (Z)-Endoxifen with a standard treatment regimen of exemestane and goserelin. The successful enrollment of 12 patients signifies the trial’s progression towards evaluating (Z)-Endoxifen’s efficacy and safety in this patient population.
Furthermore, Atossa has announced updates to its protocol for a clinical study examining the effectiveness of (Z)-Endoxifen combined with abemaciclib (VERZENIO), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in women with newly diagnosed ER+/HER2- breast cancer. This combination treatment aims to enhance therapeutic outcomes and respond to the growing need for personalized medicine in oncology.
Atossa Therapeutics’ ongoing efforts with (Z)-Endoxifen reflect the company’s commitment to innovating therapies for breast cancer, underscoring its potential role not only in treatment but also in prevention strategies. As the clinical trials progress, the results may contribute significantly to the landscape of breast cancer management, focusing on improving patient outcomes and addressing specific medical challenges in oncology.
Comments